Search Medical Condition
Please enter condition
Please choose location from dropdown

Psychosis Clinical Trials

A listing of Psychosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (116) clinical trials

A phase III study to evaluate weight gain of ALKS3831 compared to olanzapine in adults with schizophrenia

Phase

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

The primary goals of this proposal are to investigate the etiological mechanisms associated with antidepressant-related dysfunctional emotional arousal and to characterize baseline neurobiological risk factors that predict the development of dysfunctional emotional arousal in treatment seeking youth with a family history of BD. Antidepressants have moderate benefit for treating mood ...

Phase N/A

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

Study Design: Subjects will be ten patients with MDD identified via the Structured Clinical Interview for DSM-IV, manifesting a current major depressive episode of disabling severity, refractory to prolonged treatment trials with conventional medication, electro-convulsive therapy (ECT) and psychotherapy. A marked impact of depression on their health and functional status ...

Phase N/A

Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia

Positron Emission Tomography (PET) studies have demonstrated that a therapeutic window of dopamine D2/3 receptor occupancy (60-80%) is associated with clinical response in younger patients with schizophrenia. This observation has been used to predict the therapeutic dose range and contributed to current recommended antipsychotic doses. To date, there is no ...

Phase N/A

Dominantly Inherited Alzheimer Network (DIAN)

Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested: First, that there is ...

Phase N/A

Bipolar Research And Innovation Network - BRAIN

Norway is both social, genetically and culturally a homogeneous society. The health service is public and has a nearly total responsibility for psychiatric care in given catchment areas. This provides excellent opportunities to describe the frequencies and patterns of the broad spectrum of bipolar illness, including co-morbid substance use disorders, ...

Phase N/A

Alzheimer's Disease Genetics Study

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are ...

Phase N/A

Cellular Aging and Neurobiology of Depression Study

Following an initial telephone screen to assess inclusion and exclusion criteria, the evaluation will continue with an in-person evaluation to assess the presence or absence of active medical history and history of major psychiatric illness, as well as review of the consent document. If found to be eligible, participants would ...

Phase

Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.

Scientific background: Identifying Alzheimer's disease (AD) as early as possible should enable to propose a re-education platform that would fit the early stage of neuronal loss in this pathology. Neuropsychological evaluations are currently one of the main tools for the early screening of AD. Among the tests proposed during those ...

Phase N/A

Gabapentin in Patients at Clinical Risk for Psychosis

The purpose of this study is to test the effects of the drug gabapentin on brain function thought to be important in the development of schizophrenia. Researchers think that treating a brain region with gabapentin (the hippocampus) may reduce the risk for developing schizophrenia.

Phase